Nonprofit Revives Shelved Gene Therapy After Bloomsbury Genetic Therapies Shuts Down

A gene therapy left in limbo after U.K. startup Bloomsbury Genetic Therapies shut down last year is getting a second chance. The company, which had dosed just one patient before ceasing operations, has handed its lead program to a nonprofit organization dedicated to advancing treatments that might otherwise be abandoned. The nonprofit, whose name was not disclosed in the original report, will now take over development of the experimental therapy, aiming to push it toward clinical trials and, potentially, regulatory approval. This move highlights a growing trend in biotech: rescuing promising therapies that fall victim to financial or strategic setbacks, rather than letting them disappear. For patients with rare diseases, such efforts can mean the difference between a dead end and a viable treatment path. The therapy’s specifics, including its target disease and mechanism, were not detailed in the source, but the revival signals renewed hope for a program that had been effectively shelved. As more startups face funding challenges, nonprofits may play an increasingly vital role in keeping innovative science alive. The next steps will be critical to see if this therapy can overcome its past hurdles.